3rd Quarter - Amendment

HIMS & HERS HEALTH, INC. for HIMS & HERS HEALTH, INC.

Firm
Client
Income
—
Expenses
$330,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 20, 2025 $310,000 Replaced
3rd Quarter - Amendment Oct 20, 2025 $320,000 Replaced
3rd Quarter - Amendment (this page) Jan 23, 2026 $330,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances Discussions concerning proposed legislation related to access to compounded drugs and drug shortages H.R.5316 - Drug Shortage Compounding Patient Access Act of 2025 H.R.4605 - End Prescription Drug Ads Now Act H.R.238 - Healthy Technology Act of 2025 S.5040 - Protecting Patients from Deceptive Drug Ads Online Act S.2068 - End Prescription Drug Ads Now Act

LobbyistCovered position, as disclosed
SONYA ELLING —
WHITNEY JONES New Health Policy Analyst, Sen. Rep. Pol. Comm. (2018-2022)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4605 (119th), S. 2068 (119th), S. 5040 (119th), H.R. 238 (119th), H.R. 5316 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.